Atlas Trials

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

Clinical trial NCT07467993 · RECRUITING

Trial details

NCT number
NCT07467993
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2026-03-16
Primary completion
2027-07-29
Enrollment
142

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.